08045804946
Send Inquiry
AVEVA 250MG INJ
3000.0 INR/Number
Product Details:
- Packaging Type Vial
- Pacakaging (Quantity Per Box) 1 vial per box
- Origin of Medicine India
- Life Span 24 Months from manufacturing date
- Salt Composition Adalimumab
- Brand Name AVEVA
- Indication Rheumatoid arthritis, Crohns disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis
- Click to View more
X
AVEVA 250MG INJ Price And Quantity
- 3000.0 INR/Number
- 1 Number
- ~148 kDa (Adalimumab)
- Clear to slightly opalescent
- Monoclonal Antibody
- Prescription
- L04AB04
- Subcutaneous
- Intas Pharmaceuticals Ltd.
- Injection site reactions, headache, upper respiratory tract infections
AVEVA 250MG INJ Product Specifications
- 1 vial per box
- Vial
- 1 Vial
- India
- 24 Months from manufacturing date
- Administer under medical supervision
- Adalimumab
- Adults
- Injection
- Biological
- AVEVA
- Adults and adolescents with autoimmune conditions
- Immunosuppressive- reduces inflammation and modifies immune responses
- Store in a refrigerator (2C - 8C), do not freeze
- As directed by physician
- Rheumatoid arthritis, Crohns disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis
- Adalimumab 250mg
- Injection
- ~148 kDa (Adalimumab)
- Clear to slightly opalescent
- Monoclonal Antibody
- Prescription
- L04AB04
- Subcutaneous
- Intas Pharmaceuticals Ltd.
- Injection site reactions, headache, upper respiratory tract infections
AVEVA 250MG INJ Trade Information
- 1000 Number Per Week
- 2 Days
- No
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- All India
Product Description
- Active Ingredient: Fulvestrant (250 mg per 5 ml vial/pre-filled syringe).
- Manufacturer: Zydus Cadila.
- Mechanism of Action: Fulvestrant binds to estrogen receptors in cancer cells and causes them to degrade. This action blocks the effect of estrogen, a hormone that can stimulate the growth of certain breast cancer cells, thereby slowing or stopping tumor growth.
- Usage: It is used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in women after menopause. It can be used alone (monotherapy) or in combination with other anti-cancer drugs like palbociclib.
- Administration: The medication is administered by a healthcare professional as a slow, deep intramuscular injection, typically into the gluteal muscle (buttocks). The typical initial dose is 500 mg (two 250 mg injections) on specific days, followed by monthly maintenance doses.
- Storage: Must be stored in a cold chain (between 2-8C).
Targeted Therapy for Autoimmune Disorders
AVEVA 250MG INJ offers advanced immunosuppressive therapy, specially formulated for those suffering from chronic autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and more. This biologic medication targets and modifies immune responses, reducing inflammation and preventing disease progression.
Safe Administration and Storage
This product must be administered via subcutaneous injection under medical supervision to ensure safety and efficacy. It is packaged in a single-use vial and should be stored in a refrigerator at 2C-8C. Importantly, freezing must be avoided to maintain the stability of the active ingredient.
Proven Relief for Adults and Adolescents
Approved for use in adults and adolescents, AVEVA 250MG INJ has shown effectiveness in managing symptoms, reducing flare-ups, and improving quality of life for those with autoimmune conditions. Adalimumab, the active component, has a strong clinical record in controlling inflammation and modifying immune system activity.
FAQ's of AVEVA 250MG INJ:
Q: How should AVEVA 250MG INJ be administered?
A: AVEVA 250MG INJ is given as a subcutaneous injection, usually by a healthcare professional. Always follow your physician's instructions and do not attempt to self-inject unless explicitly trained and approved by your healthcare provider.Q: What types of health conditions is AVEVA 250MG INJ recommended for?
A: This injection is indicated for adults and adolescents with autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.Q: When should I administer or receive my dose of AVEVA 250MG INJ?
A: The dosage and frequency are determined by your doctor based on your individual medical condition. Always stick to the schedule provided by your healthcare provider for the best results.Q: Where should I store AVEVA 250MG INJ?
A: AVEVA 250MG INJ must be kept in a refrigerator between 2C and 8C. Avoid freezing the medication and ensure it remains in its original packaging until use.Q: What is the process if I experience side effects such as injection site reactions or headaches?
A: Although mild side effects like local reactions or headache are possible, report any unusual or severe symptoms to your physician promptly for proper management.Q: How does AVEVA 250MG INJ benefit people with autoimmune conditions?
A: By targeting specific pathways in the immune system, AVEVA 250MG INJ reduces inflammation, alleviates symptoms, and can help prevent further joint or tissue damage associated with chronic autoimmune diseases.Q: What precautions should I take while using AVEVA 250MG INJ?
A: Always use AVEVA 250MG INJ under medical supervision, adhere to recommended storage instructions, and inform your doctor of any existing infections or health issues before starting treatment.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Anti Cancer Medicines' category
Contact Us
- Office No. - 5, Ground Floor, D R Shopping Center, Dattapada Road, Near Hdfc Bank, Borivali East,Mumbai - 400066, Maharashtra, India
- Phone : 08045804946
- Mr Ranjeet Singh (CEO & Founder)
- Mobile : 08045804946
- medisus.pharma007@gmail.com
Send Inquiry
Send SMS
Call Me FreeMEDISUS PHARMA
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
